Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook

By The Northwire Desk — AI Analysis Dec 02, 2025 · 07:00 NURS · 3.43 Hydreight Technologies Inc.
NURS · Price

Executive Summary

  • Hydreight Technologies reported Q3 2025 GAAP revenue of $10.52 M (↑132% YoY) and GAAP net income of $362 K, marking a turnaround from a loss in Q3 2024.
  • Adjusted EBITDA reached $620 K and cash on hand stood at $18.64 M, underscoring strong liquidity and profitability.
  • The company highlighted rapid growth in its multi‑vertical platform (especially VSDHOne), nurse network expansion (+49% YoY sign‑ups), and a 72% YoY increase in pharmacy order volume, positioning it for continued scaling into 2026.

Key Details

  • Q3 2025 Financial Highlights
  • GAAP revenue: $10.52 M (↑132% YoY)
  • Topline revenue (non‑GAAP): $12.83 M (↑110% YoY)
  • Gross margin: $2.33 M (up from $1.53 M in Q3 2024)
  • Adjusted EBITDA: $620 K
  • GAAP net income: $362 K vs. a loss of $90 K in Q3 2024

  • Cash on hand at quarter‑end: $18.64 M

  • First Nine Months (FY 2025) Metrics

  • Topline revenue: $26.71 M (↑61% YoY)
  • GAAP revenue: $20.44 M (↑70% YoY)

  • Adjusted margin: 28.21%

  • Multi‑Vertical Platform – GLP‑1 treatments now represent ~28% of activity; other verticals include TRT, peptides, NAD+, hair loss, genetics, sexual‑health products, ondansetron, and additional categories in development.

  • Nurse Network & Clinic Adoption

  • 198 new nurse sign‑ups (July–Sept 2025) vs. 133 same period prior year (+49% YoY).

  • 593 nurse sign‑ups YTD 2025 vs. 364 YTD 2024 (+63% YoY).

  • Pharmacy Volume – Orders up ~72% YoY, reflecting repeat usage and broader category adoption.

  • VSDHOne Platform (launched late June 2025)

  • Q3 2025 product orders placed: ≈295,000.
  • YTD as of Dec 1 2025 total product orders placed: ≈887,000.

  • Company on track to meet 2025 target of ~1.3 M product orders placed.

  • Strategic Initiatives

  • Acquired a 5% stake in Perfect Scripts (option to increase).
  • Evaluating profitable multi‑state operators and expanding into genetics, NAD+, oral weight‑management.

  • Ongoing growth of partner ecosystem across the U.S.

  • Compliance & Infrastructure – Nationwide licensed physicians, state‑by‑state telehealth compliance, integrated 503A/503B pharmacy partners, secure prescribing/fulfillment networks.

  • Margin Model & AOV Drivers – Margins vary by treatment category; multi‑vertical adoption improves blended margins; automation and workflow enhancements expected to boost long‑term efficiency.

  • 2026 Framework – Focus on margin discipline, increased automation, stronger onboarding processes, expanded multi‑vertical adoption, reinforced compliance and operational infrastructure.

  • Guidance – Full 2026 guidance slated for release in mid‑December 2025.

Notable Quotes

“We continue to focus on building Hydreight with a structured and deliberate approach… The recent results and platform activity reflect the infrastructure, partnerships, and operational foundation we have put in place over the past several years.” – Shane Madden, CEO

“Our priorities for 2026—automation, onboarding processes, and multi‑vertical support—are based on ongoing analysis of partner behavior and workflow requirements.” – Shane Madden, CEO

Read the original news release →

More from Hydreight Technologies Inc.

Jun 01, 2026 · 21:32

Hydreight's Q1 EBITDA Margin Expansion Validates Operating Leverage, But Valuation Premium Demands Flawless Execution

Earnings May 01, 2026 · 00:14

Victory Square Technologies Inc.

Earnings Apr 30, 2026 · 20:56

Hydreight Validates Profitability Model But Aggressive 2026 Guidance Looms

Earnings Mar 13, 2026 · 18:43

Hydreight closes acquisition of 800,000 Insu units

M&A / Property Mar 13, 2026 · 16:15

Hydreight Technologies Closes Strategic Investment in Insu Therapeutics

Financings Mar 09, 2026 · 08:00

Hydreight Announces Normal Course Issuer Bid

Other